Waters Corporation (WAT) Q3 2026 earnings review
Waters' original lab business accelerates, while acquired units grow 1%
Waters Corporation, a maker of laboratory testing instruments and medical diagnostic supplies, is riding fast growth in its original business while the Becton Dickinson units it bought in February barely advance. Sales from businesses owned a year ago rose 10% in constant currency as drugmakers replaced lab equipment and bought chemical consumables, lifting profit per share excluding one-offs by 21%. By contrast, sales at the acquired biosciences and diagnostics units grew 1% from a year ago, and merger integration bills cut free cash flow by more than half. Even so, chief executive Udit Batra raised every part of the full-year outlook and set the fourth-quarter underlying sales plan above what the prior full-year plan implied, by our math.
| Sales from businesses owned a year ago | $871M +9% from a year ago (+10% constant currency) |
|---|---|
| Acquired business comparable sales | $896M +1% from a year ago |
| Profit per share, excluding one-offs | $4.10 +21% from a year ago |
| Full-year total revenue outlook | Raised $43M middle of the range: $6.488B |
⚖️ Verdict: 🟢 Bullish
The story got better because the original lab equipment business accelerated to double-digit constant-currency growth and management removed the fourth-quarter slowdown that its prior full-year outlook implied. One caution: the acquired divisions slowed from 4% comparable growth last quarter to 1% this quarter, and their planned fourth-quarter rebound to about 7% growth, by our math, rests on comparing against a weak late-2025 period when those units shrank 8%.
The question now is whether the acquired Becton Dickinson businesses are genuinely turning around under Waters' management or merely bouncing off depressed prior-year comparisons. If new cell-analysis instruments, hospital reagent contracts and price increases are taking hold, growth will hold near mid-single digits; if the rebound is just an easy comparison, growth will stall once the weak base passes. First-quarter 2027 comparable sales, after the merger passes its one-year mark, will settle it.
🐂 Bull Case
Legacy Lab Equipment and Consumables Reached 10% Growth
Waters makes laboratory machines and chemical supplies that drugmakers use to test medicines. Sales from businesses it owned a year ago rose 9% to $871 million, or 10% in constant currency, beating the top of its $850 million to $867 million plan. Chief executive Udit Batra said "LC-MS instrument growth also strengthened, growing double-digits in constant currency, driven by robust instrument replacement trends, idiosyncratic growth drivers across GLP-1s, PFAS and India generics".
- Analytical Sciences Division (ASD, the main lab equipment unit): $703 million, up 8% as reported and 9% in constant currency
- ASD instruments (liquid chromatography and mass spectrometry, or LC-MS, machines): $282 million, up 10% in constant currency
- ASD chemistry consumables (columns and chemical kits used in each test): $157 million, up 12% in constant currency
- Clinical Business Unit (hospital testing equipment moved into Advanced Diagnostics): $75 million, up 17%
This matters because the original Waters business is doing the heavy lifting while the newly acquired units grow slowly. Customers are replacing aging lab instruments and running more tests for weight-loss drugs (GLP-1s) and water contaminants (PFAS, or forever chemicals), so high-margin chemical supplies grow alongside machine sales.
What to watch: constant-currency instrument growth in the fourth quarter. Holding near 10% despite three fewer working days would show the multi-year equipment replacement cycle still has momentum heading into 2027.
Waters Lifted Its Fourth-Quarter Plan Above Implied Targets
Last quarter, Waters left its full-year outlook where it implied a sharp fourth-quarter slowdown for businesses it owned a year ago. By our math, that earlier plan pointed to $945 million to $989 million of fourth-quarter underlying sales. Today the company set its explicit fourth-quarter outlook at $984 million to $1.002 billion, or 7% to 9% constant-currency growth.
By our math, the middle of the new fourth-quarter range sits $26 million above the prior implied plan and calls for a 14.0% jump from the third quarter. That step-up is much closer to the 15% to 18% fourth-quarter seasonal jump the business recorded from 2023 through 2025, especially since this fourth quarter has three fewer working days.
What to watch: fourth-quarter underlying sales against the $1.002 billion top of the range. Another finish at or above the high end would mark eight straight quarters of meeting or beating its top-line plan.
Lower Overhead Kept Margins Steady and Lifted Profit
In February 2026, Waters bought the Biosciences and Diagnostic Solutions (BDS) businesses from Becton, Dickinson and Company, which carry lower profit margins than legacy Waters. Gross margin excluding one-offs (profit after the cost of making products) fell 3.2 percentage points from a year ago to 55.8%, by our math. Yet operating margin excluding one-offs barely moved, dipping 0.2 percentage points to 30.1%.
Waters protected its operating margin because it cut selling and administrative overhead (salaries and office costs) by 2.8 percentage points of revenue, to 19.8%, and trimmed research and development by 0.3 points, to 5.9%. Those savings helped profit per share excluding one-offs rise 21% to $4.10, even though share count rose 65% and net interest expense jumped from $8 million to $53 million to pay for the merger.
What to watch: fourth-quarter profit per share excluding one-offs against the $4.58 to $4.68 outlook. Profit growth slows to 1% to 3% in the plan as the company laps a high prior-year base.
Positives this quarter didn't test
Four standing drivers from prior quarters were not broken out in the third-quarter earnings release because their detailed tables live in the conference call remarks or the quarterly filing.
- Acquired-business price increases: reached 0.9% in the second quarter toward a 1.5% goal; the conference call will show if the 0.9% pace held.
- Drugmaker factory reshoring: Waters tracks 76 US manufacturing sites under construction; management promised a 2027 growth framework on the call "outlining how reshoring, synergies and AI-related demand drivers are expected to shape next year's growth".
- China pharmaceutical recovery: grew double digits in the first half for legacy Waters; the quarterly filing will show third-quarter regional pharma trends.
- US Academic and Government demand: rebounded 11% in the second quarter; the filing's end-market table will show if university and government lab spending stayed positive.
🐻 Bear Case
Acquired Growth Slowed to 1% Ahead of Easy Comparisons
Waters paid $12.8 billion in debt and stock for the BDS businesses to add biological reagents and hospital infection tests. Chief executive Udit Batra said "we are delivering ahead of schedule on our synergy and integration commitments for our acquired businesses", and added that "our fourth quarter guidance calls for double digit growth in both our organic and acquired businesses on a days adjusted basis".
The numbers in the release tell a slower story. Total acquired sales grew 1.2% from a year ago on a comparable basis to $896 million, down from 4.0% growth in the second quarter, and beat the $895 million target by $1 million. Within the deal, Biosciences (WBD, cell-analysis instruments and reagents) grew 2.3% to $396 million as reagent growth accelerated by 4 percentage points, while Diagnostic Solutions (microbiology and hospital testing) grew 0.4% to $500 million.
Third-quarter growth slowed because the comparison period included a $20 million inventory buildup before Becton Dickinson's fiscal year-end. By our math, the fourth-quarter target of $817 million implies 6.7% comparable growth, but that compares against a weak late-2025 quarter when BDS revenue fell 8.2% to $766 million. Beating a depressed comparison does not prove the acquired businesses can grow past mid-single digits on their own.
What to watch: first-quarter 2027 comparable sales growth for the acquired businesses. That period laps the merger close and tests whether the new divisions can grow at 5% or better without easy comparisons.
Merger Bills and Working Capital Cut Cash Flow 58%
While profit excluding one-offs rose strongly, cash generation and reported accounting profit went the other way. Free cash flow excluding one-offs fell 58% from a year ago to $68 million, and the share of profit excluding one-offs that turned into cash dropped to 17%, by our math. Reported net income fell 46% to $81 million, or $0.82 per share.
- Working capital outflow (cash tied up in operating assets and liabilities): $384 million in Q3, and $785 million over the first nine months
- Cash due from Becton Dickinson (receivables collected by the seller under a transition agreement): rose $17 million in Q3 and $174 million over nine months
- Merger, restructuring and software system charges: $81 million before tax in Q3, plus $323 million of non-cash purchase accounting write-downs
- Capital expenditures (additions to property, plant, equipment and software): $43 million, up from $25 million a year ago
This matters because Waters took on $4.0 billion of new debt for the acquisition and suspended open-market share buybacks to pay it down. Until working capital swings stop draining operating cash, net debt—now $4.54 billion, down $7 million from last quarter—cannot fall quickly.
What to watch: fourth-quarter operating cash flow and net receivables due from Becton Dickinson. Settling the transition billing accounts should release cash and restart debt paydown.
Risks this quarter didn't answer
Three standing concerns from prior quarters could not be checked from the third-quarter earnings release alone.
- China hospital reimbursement (DRG) and export rules: dragged clinical flow cytometry down 20% and microbiology down 13% last quarter; the fourth-quarter call will show whether locally made BACTEC FXi blood-culture machines launched in China as planned.
- Post-2027 instrument replacement slowdown: management previously noted a potential 2028 pause in machine replacements; the 2027 framework on today's call will show how much factory reshoring can offset it.
- Analytical and Materials segment margin: fell 4.2 percentage points in the second quarter's filing; the third-quarter 10-Q segment footnote will show whether cost reallocations or product mix compressed legacy margins again.
👓 Other Themes
Currency Drag Eased and Industrial Testing Held Steady
Two external pressures remained manageable in the third quarter. Foreign currency translation reduced underlying sales growth by 1.0 percentage point, less than the 1.7-point drag built into the prior outlook, and Waters now expects a 0.7-point currency drag for the full year. Meanwhile, the Materials Sciences Division (MSD, thermal analysis instruments used in industrial chemical testing) grew 7% from a year ago to $93 million, matching second-quarter growth.
💲 Other KPIs
Accounts receivable—money owed by customers for delivered products—fell 26.3% from $1,987 million last quarter, by our math, after jumping from $829 million at year-end when the Becton Dickinson units joined. Even with lower total receivables, cash owed by Becton Dickinson under its transition collection agreement rose another $17 million in the quarter.
By our math, net debt (total debt of $5,133 million minus $593 million of cash) edged down 0.2%, or $7 million, from $4,547 million in the second quarter. The lab equipment maker borrowed $320 million and repaid $275 million during the quarter, as working capital outflows left little free cash flow to reduce the $4.0 billion merger borrowing.
Diluted shares rose 65.5% from 59.6 million a year ago because the US group issued 38.5 million shares to Becton Dickinson stockholders in February 2026. Share count was roughly unchanged from 98.5 million adjusted diluted shares in the second quarter, as management spent $1 million on share repurchases while prioritizing debt reduction.
🔮 Guidance
Raised. The middle of the full-year reported sales range moved up by $42.5 million to $6.488 billion, more than doubling last year's legacy revenue because of the February acquisition. This is the second straight raise since issuing the full-year outlook, and the increase is larger than the prior move: +$0M in Q1, +$15.5M in Q2, and +$42.5M in Q3.
Raised. The middle of the underlying constant-currency growth plan rose 1.4 percentage points to 9.4% (with reported underlying sales raised to $3.429–$3.447 billion, or 8.4%–8.9% growth). It is the third raise in three quarters for this measure, and the largest yet: +1.0 point in Q1, +0.75 points in Q2, and +1.4 points in Q3.
Raised. The full-year target for the acquired Becton Dickinson units from the February 9 close through year-end moved up by $5 million. It is the third straight increase, but each raise is smaller than the last: +$35M in Q1, +$10M in Q2, and +$5M in Q3.
Raised. The middle of the full-year profit per share outlook rose $0.10 to $14.65, representing 11% to 12% growth from a year ago (13% to 14% in constant currency). The company has lifted this target every quarter this year: +$0.10 in Q1, +$0.05 in Q2, and +$0.10 in Q3.
New. The plan calls for $1.810 billion at the middle of the range, up 2.4% from the third quarter and up 94.1% from last year's pre-merger fourth quarter, by our math.
New. The fourth-quarter plan calls for 8.0% constant-currency growth at the middle of the range (and $984 million to $1.002 billion as reported, or 5.5% to 7.5% growth after a 1.5-point currency drag). Growth slows from 10.0% in Q3 because Q4 has three fewer working days. If the pattern holds—Waters has beaten its midpoint by 2.0 points on average over the last four quarters—Q4 constant-currency growth would reach 10.0%, by our math.
New. The target of $817 million is down 8.8% from the third quarter's $896 million, but by our math it represents 6.7% growth against the $766 million the Becton Dickinson units recorded in the Oct–Dec 2025 quarter before the merger.
New. The plan calls for $4.63 at the middle of the range, up 12.9% from the third quarter on year-end seasonality, by our math, but up 1% to 3% from $4.53 a year ago as share dilution and debt interest weigh on the comparison.
❓ Key Questions
What drove the $384 million third-quarter working capital cash outflow?
Free cash flow excluding one-offs fell 58% to $68 million because operating assets and liabilities consumed $384 million in Q3 ($785 million over nine months), even as total accounts receivable dropped by $523 million from Q2.
Did price increases on acquired products hold at 0.9%?
Lifting net price realization on the Becton Dickinson businesses from 0.5% to 0.9% was a key second-quarter driver toward a 1.5% goal, but the third-quarter release did not update the figure.
How are hospital reimbursement rules and local manufacturing affecting China?
China hospital payment reforms and export licenses cut clinical flow cytometry by 20% and microbiology by 13% last quarter, and Waters planned to launch locally made BACTEC FXi blood-culture machines in China in Q4.
Did legacy Analytical and Materials segment margins compress again?
In the second quarter's filing, operating margin for the legacy segment fell 4.2 percentage points from a year ago; investors need the third-quarter filing footnote to see if shared cost reallocations or product mix hurt margins again.
How did deferred revenue and contract backlog move in Q3?
The earnings release omits deferred revenue and unfulfilled performance obligations, which stood at $603 million and $617 million in the second-quarter filing and show whether customer advance bookings match 10% underlying sales growth.